AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 261 min read$TREX

Rudolph Jacob T. sold $70K of TREX

Rudolph Jacob T. (SVP, CHRO) sold 1,400 shares of TREX CO INC (TREX) at $50.00 on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rudolph Jacob T.
Published Jun 26, 2026, 6:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 6:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TREX
Neutral
medium confidence
Mentioned
$TREX
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TREXNeutralLow
01

Why it matters

A planned insider sale provides limited incremental information about near-term fundamentals; it may slightly affect sentiment but is unlikely to drive price by itself.

02

Market read

Traders may note the filing for sentiment monitoring, but the planned nature of the sale limits trading edge.

03

What to watch

Insider sales can be misread; traders should compare with prior Form 4 activity and whether other insiders/large holders are changing positions.

Relevance 2/10Novelty 3/10Timing: after-hours/filing update (Form 4 filed 2026-06-26)

Background

The article is an SEC Form 4 insider transaction disclosure for TREX CO INC.

Company-level read

Ticker impact

$TREXNeutralMedium confidence
Context

SEC Form 4 shows TREX SVP/CHRO Rudolph Jacob T. sold 1,400 shares at $50 on 2026-06-25 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move from this single, planned sale; any impact would be short-lived sentiment noise.

Evidence & confidence

The filing is a Form 4 insider transaction with an explicitly pre-arranged 10b5-1 plan, reducing interpretability as a new negative fundamental signal.

Market effects

Sector

Minimal; this is company-specific insider trading with no sector-wide catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • issuer
    TREX CO INC

    Company whose insider transaction was disclosed on SEC Form 4.

  • insider
    Rudolph Jacob T.

    SVP, CHRO who sold 1,400 shares at $50 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TREX insider trading history →

Related articles

OCT 9
HighAI 8/10

TRex Bio, Clinical-Stage Immunology Biopharma, Files for Nasdaq Global Select Market IPO

TRex Bio filed for a Nasdaq IPO, offering 8,333,334 shares at $14.00 each, aiming to raise $116.7 million. The company, focused on immunoregulatory medicines, plans to use proceeds for clinical trials and general corporate purposes. Eli Lilly has shown interest in purchasing shares. TRex Bio's lead candidate, TRB-061, is in Phase 1b trials for atopic dermatitis, with data expected in mid-2027.

tradingview.com2 min
OCT 9
HighAI 8/10

TRex Bio raises $116.7 million in IPO priced at $14 a share

TRex Bio Inc. raised $116.7 million in its IPO, priced at $14 per share. J.P. Morgan and Evercore led the offering, indicating institutional confidence. The company focuses on immunology, an area of sustained investor interest. All shares were pre-allocated to institutional buyers, with the first public trading opportunity upcoming.

247wallst.com2 min
OCT 9
HighAI 8/10

TRex Bio IPO raises $116.7 million, prices at bottom of range

TRex Bio Inc. raised $116.7 million in its U.S. IPO, pricing shares at $14, the bottom of its $14-$16 range. The biotech company sold 8.3 million shares, giving it a market value of about $384 million. Proceeds will fund clinical trials for its lead drug candidate, TRB-061. Shares will trade on Nasdaq under the ticker TRXB. The company reported a net loss of $34.8 million in 2025, up from $3.1 million the prior year.

finance.yahoo.com2 min
OCT 9
HighAI 8/10

TRex Bio prices $117M IPO to support immune drug work

TRex Bio priced its IPO at $117M, selling 8.3M shares at $14 each, and will trade on Nasdaq under 'TRXB'. The company is developing immune drugs, with TRB-061 in Phase 1 trials and TRB-071 planned for testing. Eli Lilly, its largest shareholder, may also buy IPO shares. TRex has raised $220M in venture financing. Another biotech, Retension Pharmaceuticals, also went public with a $45M offering, highlighting increased biotech IPO activity in 2026.

finance.yahoo.com2 min
OCT 9
HighAI 9/10

TRex Bio, Inc. Prices $116.7M IPO at $14

TRex Bio priced 8.3M shares at $14 each, raising $116.7M in its IPO. Trading begins Oct. 9 on Nasdaq under ticker TRXB. Underwriters have a 30-day option for 1.25M more shares. The company plans to use proceeds for its clinical-stage immunology pipeline.

tradingview.com1 min